Global Automated Breast Ultrasound System Market Size By Type (Automated Breast Ultrasound System, Automated Breast Volume Scanner), By Application (Hospitals, Diagnostic Imaging Laboratories), By Reg...

The Global Automated Breast Ultrasound System (ABUS) Market was valued at USD 2.1 billion in 2023 and is projected to reach USD 4.3 billion by 2031, expanding at a CAGR of 9.3% during the forecast period of 2023–2031. The growth of the ABUS market is primarily driven by the increasing incidence of breast cancer, especially in women with dense breast tissue where traditional mammography has limitations. The demand for supplementary imaging tools like ABUS is rapidly rising due to its ability to provide consistent and reproducible 3D images, improving cancer detection rates. Additionally, increasing awareness campaigns and favorable reimbursement policies are fueling market expansion globally.

Drivers:

Rising Incidence of Breast Cancer:

Breast cancer remains one of the leading causes of cancer-related deaths in women worldwide. The need for advanced screening techniques such as ABUS has increased, particularly for women with dense breast tissues where traditional mammography may not be sufficient.

Advantages Over Conventional Ultrasound:

ABUS systems offer standardized imaging, high reproducibility, and greater efficiency compared to handheld ultrasounds. These features are leading healthcare providers to adopt ABUS as a complementary tool alongside mammography.

Increasing Awareness and Screening Programs:

Governments and non-profit organizations are investing heavily in breast cancer awareness and early detection programs, especially in developed nations. These initiatives are boosting the demand for advanced diagnostic tools like ABUS.

Restraints:

High Equipment Costs:

The initial investment required for ABUS systems can be substantial, particularly for smaller clinics and diagnostic centers in developing countries. This financial barrier limits widespread adoption in price-sensitive regions.

Limited Trained Personnel:

Although automated, ABUS still requires radiologists with specific training to interpret the results accurately. The shortage of trained professionals remains a key challenge, especially in rural and underdeveloped areas.

Opportunity:

Integration with Artificial Intelligence (AI):

AI-assisted image interpretation is revolutionizing diagnostic imaging, including ABUS. Integration with AI is expected to enhance diagnostic accuracy, reduce radiologist workload, and offer new growth avenues for market players.

Expansion into Emerging Markets:

Rapid urbanization and healthcare infrastructure development in countries like India, Brazil, and China present a lucrative opportunity for ABUS manufacturers. Increased healthcare spending and public-private initiatives are facilitating this expansion.

Market by System Type Insights:

Based on system type, the Automated 3D Ultrasound System dominated the global ABUS market in 2023. This segment is expected to retain its leading position throughout the forecast period due to its enhanced imaging capabilities and superior diagnostic accuracy. The Handheld Ultrasound System, while still used, is witnessing a decline in preference owing to operator dependency and variability in results.

Market by End-use Insights:

In terms of end-use, Hospitals held the largest market share in 2023, accounting for over 45% of the global revenue. Hospitals typically have the budget and infrastructure to integrate ABUS into their diagnostic workflows. Diagnostic Imaging Centers are also expected to witness significant growth due to rising demand for early breast cancer detection and outsourced imaging services.

Market by Regional Insights:

Geographically, North America led the global ABUS market in 2023, driven by advanced healthcare infrastructure, high breast cancer prevalence, and strong reimbursement frameworks. However, Asia-Pacific is expected to register the fastest growth rate during the forecast period, supported by rising healthcare investments, growing awareness, and increasing adoption of modern diagnostic technologies.

Competitive Scenario:

Key players operating in the global ABUS market include GE HealthCare, Siemens Healthineers, Canon Medical Systems, Hitachi, Ltd., iVu Imaging Corporation, SonoCiné Inc., and QView Medical, Inc. These companies are focusing on product innovation, strategic collaborations, and regional expansions.

In 2023, GE HealthCare launched an upgraded version of its Invenia ABUS system featuring enhanced image processing powered by AI.

In 2024, Siemens Healthineers partnered with a leading oncology institute to evaluate ABUS efficiency in dense breast screening programs.

Canon Medical Systems expanded its footprint in Southeast Asia in 2025 through strategic distributor partnerships targeting mid-sized diagnostic clinics.

Scope of Work – Global Automated Breast Ultrasound System Market

Report Metric Details

Market Size (2023) USD 2.1 billion

Projected Market Size (2031) USD 4.3 billion

CAGR (2023–2031) 9.3%

Market Segments By System Type (3D ABUS, Handheld), End-use (Hospitals, Imaging Centers), Region

Growth Drivers Rising breast cancer incidence, advantages over traditional imaging, increased awareness

Opportunities AI integration, expansion in emerging markets

Key Market Developments:

2023: GE HealthCare launched Invenia ABUS 2.0 with advanced AI algorithms to enhance lesion detection in dense breasts.

2024: Siemens Healthineers entered a clinical partnership with a U.S.-based cancer research institute to study ABUS efficacy in early-stage detection.

2025: SonoCiné announced FDA clearance for its second-generation ABUS device targeting rap